Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Accured Expenses (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Change in Accured Expenses for 7 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 75.29% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.2 million, a 419.6% decrease, with the full-year FY2025 number at -$12.2 million, down 419.6% from a year prior.
  • Change in Accured Expenses was -$1.5 million for Q4 2025 at Pliant Therapeutics, up from -$2.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.8 million in Q2 2022 to a low of -$6.1 million in Q4 2024.
  • A 5-year average of $251000.0 and a median of -$387500.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 9871.43% in 2021, then plummeted 976.68% in 2024.
  • Pliant Therapeutics' Change in Accured Expenses stood at $2.0 million in 2021, then tumbled by 120.8% to -$411000.0 in 2022, then skyrocketed by 270.07% to $699000.0 in 2023, then tumbled by 976.68% to -$6.1 million in 2024, then soared by 75.29% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Change in Accured Expenses are -$1.5 million (Q4 2025), -$2.0 million (Q3 2025), and -$3.8 million (Q2 2025).